Basilea PharmaceuticaXSWX:BSLN -0.57%62 Current Ratio is 5.11 as of Dec. 2025, which is 38% above its 10-year median of 3.69. GuruFocus rates XSWX:BSLN with a GF Score™ of 62/100 and a GF Value™ of CHF57.38 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Basilea Pharmaceutica ranks better than 58.22% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Basilea Pharmaceutica's current ratio for the quarter that ended in Dec. 2025 was 5.11.
Basilea Pharmaceutica has a current ratio of 5.11. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Basilea Pharmaceutica's Current Ratio or its related term are showing as below:
XSWX:BSLN'
s Current Ratio Range Over the Past 10 Years
Min: 1.38 Med: 3.69 Max: 5.11
Current: 5.11
During the past 13 years, Basilea Pharmaceutica's highest Current Ratio was 5.11. The lowest was 1.38. And the median was 3.69.
XSWX:BSLN's Current Ratio is ranked better than 58.22% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs XSWX:BSLN: 5.11
Basilea Pharmaceutica (XSWX:BSLN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Basilea Pharmaceutica Current Ratio Related Terms
Basilea Pharmaceutica Current Ratio Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Current Ratio distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Current Ratio of 5.11 as of Dec. 2025. This is 38% above median its historical median of 3.69. Over the past decade, Basilea Pharmaceutica's Current Ratio has ranged from 1.38 to 5.11. According to the industry distribution chart, Basilea Pharmaceutica ranks #590 out of 1412 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Basilea Pharmaceutica's Current Ratio too high?
Basilea Pharmaceutica's current Current Ratio of 5.11 is 38% above median its 10-year median of 3.69. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 5.11. The Biotechnology industry median Current Ratio is 3.89. Basilea Pharmaceutica's value of 5.11 is 31.4% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #590 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #590 out of 1412 companies for Current Ratio. This puts Basilea Pharmaceutica in the upper half of its industry. The industry median Current Ratio is 3.89. Basilea Pharmaceutica's value of 5.11 is 31.4% above this benchmark. Historically, Basilea Pharmaceutica's own Current Ratio has ranged from 1.38 to 5.11 over the past decade. While the company's 10-year median is 3.69 vs. the industry median of 3.89, Basilea Pharmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Current Ratio of 5.11 is 31.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Current Ratio is 5.11, which is 38% above median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF51.90 — trading 9.6% below its estimated fair value. The current Current Ratio is 5.11, which is 38% above median its 10-year median of 3.69 and 31.4% above the Biotechnology industry median of 3.89. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Current Ratio is 5.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Current Ratio: 5.11 (38% above median its 10-year median of 3.69)
GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
Industry Position: 31.4% above the Biotechnology median (#590 of 1412)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
